NCT02799823终止不适用
Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Early Feasibility Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- HLT Inc.
- 入组人数
- 11
- 试验地点
- 9
- 主要终点
- Primary Endpoint: Mortality at 30 days
研究概览
简要总结
The purpose of this study is to evaluate the safety and performance of the HLT System in patients with severe aortic stenosis who present at High Risk for aortic valve replacement surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •70 years of age or older
- •Echocardiographic or hemodynamic based evidence of calcific (senile) aortic stenosis with one of the following: aortic valve EOA <1.0 cm2 or 0.6 cm2/m2, mean aortic valve gradient >40 mmHg or peak aortic valve velocity >4 m/sec
- •Symptoms due to aortic stenosis resulting in one of the following:
- •New York Heart Association (NYHA) Functional Classification of II or greater
- •Presence of angina
- •Presence of syncope
- •Documented aortic valve annular diameter ≥ 21 and ≤ 24 mm (associated perimeter range is 66.0 - 75.4 mm or associated area range of 346 - 452 mm2) measured by the multislice computed tomography (MSCT) Core Lab assessment of pre-procedure imaging.
- •Documented heart team agreement of high risk for surgical aortic valve replacement (SAVR) due to frailty or comorbidities such as:
- •Society of Thoracic Surgeons (STS) score of ≥8%
- •Frailty as indicated by one of the following:
- •Five meter walk test > 6 seconds
- •Katz activities of daily living (ADL) score of 3/6 or less
- •Body Mass Index < 20 kg/m2
- •Wheelchair bound, unable to live independently
- •Childs Class A or B liver disease
- •Severe lung disease (need for supplemental oxygen, forced expiratory volume at one second (FEV1) < 50% of predicted, diffusing capacity of the lungs for carbon monoxide (DLCO) < 60%, or other evidence of severe pulmonary dysfunction
- •Previous coronary artery bypass graft(s) at risk for re-operation
- •Serum albumin < 3.5 g/dL
- •Other evidence that subject is at high risk for surgical valve replacement by one of the following:
- •Hostile chest
- •Porcelain aorta
- •Severe pulmonary hypertension (> 60 mmHg)
- •Prior chest radiation therapy
- •Neuromuscular disease that creates risk for mechanical ventilation or rehabilitation after surgical aortic valve replacement
- •Orthopedic disease that creates risk for rehabilitation after surgical aortic valve replacement
- •Geographically available, willing to comply with follow up and able to provide written informed consent
排除标准
- •Congenital unicuspid or bicuspid aortic valve, or noncalcified aortic valve; or valve eccentricity (calcific or otherwise) which could compromise procedural success.
- •Patients with a coronary height of < 10mm, or otherwise determined to be high risk for coronary obstruction
- •Patients with low flow/low gradient aortic stenosis
- •Patients with significant annular or left ventricular outflow tract (LVOT) calcification that could compromise procedural success
- •Pre-existing prosthetic heart valve in any position
- •Severe aortic, mitral or tricuspid valve regurgitation
- •Moderate to severe mitral stenosis
- •Myocardial infarction within the past 30 days*
- •Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
- •Left Ventricular Ejection Fraction (LVEF) < 30%
- •Severe pulmonary hypertension with pulmonary systolic pressure greater than two- thirds of systemic pressure
- •Hemodynamic instability requiring inotropic drug therapy within the past 14 days
- •Untreated clinically significant coronary artery disease requiring revascularization
- •Presence of significant aortic disease such as atheroma, thrombus, or aneurysm which precludes safe implant delivery
- •Blood dyscrasias defined as leukopenia (White blood cell count < 1,000 cell/mm3), anemia (hemoglobin < 9.0 g/dL), thrombocytopenia (platelet count < 50,000 cells/mm3), history of bleeding diathesis or coagulopathy
- •Patient ineligible for or refuses blood transfusions
- •Unfavorable peripheral vascular anatomy or disease (e.g. severe obstructive calcification, severe tortuosity) that would preclude passage of 18 French (18F) catheters from the femoral arterial access to the aorta as evidenced by peripheral MSCT
- •Active peptic ulcer or gastrointestinal bleeding within the past 90 days, that would not allow treatment with the protocol antiplatelet regimen post implant *
- •Symptoms of carotid or vertebral artery disease (e.g. stroke or transient ischemic attack) within past 6 months, or treatment of carotid stenosis within past two months*
- •Renal disease as demonstrated by a serum creatinine > 2.5 mg/dL or end stage renal disease
- •Active infection (including endocarditis) requiring ongoing treatment
- •Need for emergent surgery or intervention other than the investigational procedure
- •Any therapeutic invasive cardiac procedure performed or planned to perform within 30 days of the index procedure, except for percutaneous coronary intervention (PCI) which is performed within 7 days prior to the index procedure*
- •Hypersensitivity or contraindication to procedural medication and device materials (e.g. titanium, nickel, pork) which cannot be adequately premedicated
- •Life expectancy < 1 year due to non-cardiac co-morbid conditions
- •Currently participating in any investigational drug or device studies that may confound the results of this study
- •History of any cognitive or mental health status that would interfere with study participation
- •Following surgical consultation, patient is deemed inoperable in the event that surgical intervention is required after Meridian valve implantation
- •Patients with a history of hypertrophic cardiomyopathy
- •Aortic root angle ≥ 70˚ as determined by the MSCT Core Lab assessment of pre- procedure imaging
- •Unfavorable left ventricular anatomy (e.g., size or shape) as evidenced by pre- procedure imaging * At the time of procedure, if a subject's medical status has changed since enrollment, the subject shall be re-evaluated for eligibility
结局指标
主要结局
Primary Endpoint: Mortality at 30 days
时间窗: 30 days
The primary safety endpoint is all-cause mortality at 30 days.
次要结局
- Secondary Performance Endpoint 2: Post-procedural Valve Performance(pre-discharge, 1, 6, 12, 24, 36, 48 and 60 months)
- Secondary Performance Endpoint 1: Procedural Device Performance(1 day)
- Secondary Safety Endpoint 3: Adverse Events(Throughout the 5 year follow up period)
研究者
研究点 (9)
Loading locations...
相似试验
撤回
不适用
HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON CANADASevere Aortic StenosisNCT02159794HLT Inc.
已完成
不适用
HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiONSevere Aortic StenosisAortic Valve StenosisNCT02157142HLT Inc.4
终止
不适用
HLT Meridian Valve CE Mark TrialAortic Valve StenosisNCT03805711HLT Inc.1
已完成
不适用
Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Feasibility Trial CANADAAortic Valve StenosisNCT02838680HLT Inc.15
进行中（未招募）
不适用
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).Severe Aortic StenosisNCT01586910Medtronic Cardiovascular1,746